Posted by Michael Wonder on 25 May 2023
Vanflyta first FLT3 inhibitor approved in Japan for patients with newly diagnosed FLT3-ITD positive AML
25 May 2023 - First FLT3 inhibitor approved in newly diagnosed setting based on QuANTUM-First results demonstrating Vanflyta added to standard chemotherapy improved overall survival.
Daiichi Sankyo today announced that Vanflyta (quizartinib) has been approved in Japan for the treatment of acute myeloid leukaemia that is FLT3-ITD mutation positive.
